Hirudo tianjinensis Decorsin
Monomeric + oligomeric decorsin paralogs identified in Asian medicinal leech H. tianjinensis (Kalatehjari 2026) — first recombinant characterization as platelet aggregation inhibitors.
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Monomeric + oligomeric decorsin paralogs identified in Asian medicinal leech H. tianjinensis (Kalatehjari 2026) — first recombinant characterization as platelet aggregation inhibitors.
- Evidence level
- In vitro
- Drug vs leech
- Recombinant (genetically expressed)
- Safety domains
- Bleeding
Clinical translation limit
H. tianjinensis decorsin's in vitro platelet inhibition does NOT establish clinical efficacy. No FDA-approved derivative exists; H. tianjinensis is taxonomically distinct from the FDA-cleared K040187 medicinal leech species.
Molecular Profile
- Category
- Antiplatelet
- Evidence tier
- Preclinical
- Molecular weight
- 4,500 Da
- Source species
- Hirudo tianjinensis
- Discovered
- 2026 · Kalatehjari P et al.
Biological Targets
- → platelet integrin αIIbβ3 (RGD-mediated)
Key Citations
- Kalatehjari P et al. (2026), Parasitol Res · PMID 41653280
External Resources
Related Antiplatelet Compounds
Calin
Anti-platelet adhesion protein that blocks von Willebrand factor–collagen binding.
Saratin
Anti-platelet adhesion protein blocking collagen-mediated platelet activation.
Decorsin
RGD-containing peptide inhibiting platelet GP IIb/IIIa receptor — eptifibatide ancestor.
Ornatin
RGD-peptide GP IIb/IIIa antagonist — sister molecule to decorsin from a different leech species.